

//
//
//

()

in vivo

*

(NOS) :

(eNOS) NOS

(iNOS) NOS NOS

iNOS

NOS

(iv)

(iv L-N6-(1-Imino ethyl) lysine) L-NIL

(, iv N-nitro-L- Arginine Methyl Ester) L-NAME

(NAG)

(GFR)

NAG GFR L-NIL :

GFR L-NAME L-NIL

L-NAME NOS L-NIL iNOS :

NAG GFR L-NIL :

(NO)

(.)

(.)

ip iv NO
 NOS (nNOS) NOS (NOS)
 NO (iNOS) NOS (eNOS)
 iNOS NO
 (LDH)
 (NAG) ()
)
 (GFR
 iNOS ()
 power lab
 % iNOS
 in vivo
 NOS
 ANOVA Sprague-Dawley
 (P< /) Tukey :
 (iv ip) :() •
 iv) : •
 GFR ()
 (P< /) L-NIL : •
 GFR L-NIL L-N6-(1-Imino ethyl) lysine) L-NIL
 L-NAME iv
 (P< /) (P< /)
 ip
 (P< /) ()
 L-NAME L-NIL L- : •
 N-nitro-L- Arginine Methyl NAME
 Ester)

(P < /)
NAG

(P < /)

()

+ L-NAME

L-NIL

()

L-NIL

L-NAME

(P < /)


()

L-NAME

()

P < /)

(




L-NIL

p < 0.01 *

L-NIL

L-NAME

p < 0.05 **



L-NIL

P<0.01 *


L-NIL

P<0.05 #

L-NAME

P<0.05 †

P<0.01 **



L-NIL+

L-NAME+

(NAG)

-D b

N

L-NAME

P<0.01 *

P<0.05 **

() iNOS NO
 INOS NO L-NIL
 eNOS GFR
 () NAG
 iNOS L-NAME
 GFR iNOS
 () LPS NOS
 () eNOS %
 ARF
 () iNOS eNOS iNOS iNOS
 ()
 iNOS iNOS
 NOS
 L-NAME ()
 iNOS
 eNOS
 ()
 NOS
 eNOS NO
 eNOS ()
 ()
 iNOS
 L-NIL iNOS
 L-NAME NOS
 () iNOS
 ()
 iNOS
 NO

REFERENCES

1. Kone BC. Nitric oxide synthesis in the kidney: isoforms, biosynthesis and functions in health. *Nephrol* 2004; 24(4): 299-315.

-
2. Herrera M, Garvin JL. Recent advances in regulation of nitric oxide in the kidney. *Hypertension* 2005;45(6): 1062-7.
 3. Andre M, Latado H, Felley-Bosco E. Inducible nitric oxide synthase-dependent stimulation of PKGI and phosphorylation of VASP in human embryonic kidney cells. *Biochem Pharmacol* 2005; 69(4): 595-602.
 4. Kumar U, Chen J, Sapoznikov V. Overexpression of inducible nitric oxide synthase in the kidney of the spontaneously hypertensive rat. *Clin Exp Hypertens* 2005; 27(1): 17-31.
 5. Goligorsky MS, Gross SS. Nitric oxide and the kidney. New York: Chapman & Hall .1997.
 6. Yamasowa H, Shimizu S, Inoue T. Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning. *J Pharmacol Exp Ther* 2005; 312(1): 153-9.
 7. Tolle M, Levkau B, Keul P. Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. *Circ Res* 2005; 96(8): 913-20.
 8. Satoh M, Fujimoto S, Haruna Y. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. *Am J Physiol Renal Physiol* 2005; 288(6): F1144-52.
 9. Kielar ML, Jeyarajah DR, Zhou XJ. Docosahexaenoic acid ameliorates murine ischemic acute renal failure and prevents increases in mRNA abundance for both TNF-alpha and inducible nitric oxide synthase. *J Am Soc Nephrol* 2003; 14(2): 389-96.
 10. Zhang F, Siow YL. Hyperhomocysteinemia activates NF-kappaB and inducible nitric oxide synthase in the kidney. *Kidney Int* 2004; 65(4): 1327-38.
 11. Gabbai FB. Effects of nitric oxide synthase blockers on renal function. *Nephrol Dial Transplant* 2001; suppl 1(16): 10-3.
 12. Schwartz D, Brasowski E, Raskin Y. The outcome of non-selective vs selective nitric oxide synthase inhibition in lipopolysaccharide treated rats. *J Nephrol* 2001; 14(2): 110-4.
 13. Islas-Carbajal MC, Covarrubias A, Grijalva G. Nitric oxide synthase inhibition results in renal failure improvement in cirrhotic rats. *Liver Int* 2005; 25(1): 131-40.
 14. Rivas-Cabanero L, Lopez Nova M, Montero A. Increased glomerular nitric oxide synthesis in gentamicin induced renal failure. *Eur J Pharmacol* 1994; 270(1): 119-21.
 15. Rivas-Cabanero L, Rodriguez A, Lopez Nova M. Gentamicin treatment increases mesangial cell nitric oxide production. *Exp Nephrol* 1997; 5(1): 23-30.
 16. Cenk C, Sen S, Boztok N. Protective effects of oral L-arginine administration on gentamicin-induced renal failure in rats. *Eur J Pharmacol* 2000; 390: 327-34.
 17. Rivas-Cabanero L, Rodriguez-Barbero A, Arevalo M. Effect of NG-nitro-L-arginine methyl ester on nephrotoxicity induced by gentamicin in rats. *Nephron* 1995; 71(2): 203-7.